Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-resistant Epithelial Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03907527
What this trial is testing

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+31 more
Precigen, Inc 71
Large-scale testing (Phase 3)Looking for participantsNCT04921527
What this trial is testing

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerRelapsed or RefractoryChiauranib+1 more
Chipscreen Biosciences, Ltd. 454
Early research (Phase 1)UnknownNCT03283943
What this trial is testing

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
British Columbia Cancer Agency 22
Early research (Phase 1)Active Not RecruitingNCT05156892
What this trial is testing

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Who this might be right for
Ovarian Cancer
Anthony Joshua, FRACP 44
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT01653912
What this trial is testing

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Who this might be right for
Recurrent Platinum-resistant Ovarian Cancer
Accenture 59
Testing effectiveness (Phase 2)UnknownNCT03363867
What this trial is testing

BEACON - ABC in Recurrent Platinum Resistant HGSOC

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Peter MacCallum Cancer Centre, Australia 30
Testing effectiveness (Phase 2)Study completedNCT05044871
What this trial is testing

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 108
Early research (Phase 1)WithdrawnNCT02083536
What this trial is testing

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Who this might be right for
Ovarian CancerOvarian CarcinomaRecurrent Ovarian Cancer+1 more
University of Miami
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06973421
What this trial is testing

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian Cancer
Fudan University 35
Very early researchLooking for participantsNCT06660511
What this trial is testing

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Who this might be right for
Ovarian Cancer Recurrent
Second Xiangya Hospital of Central South University 5
Testing effectiveness (Phase 2)Study completedNCT02901899
What this trial is testing

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Northwestern University 45
Testing effectiveness (Phase 2)Study completedNCT00097019
What this trial is testing

Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Who this might be right for
Ovarian Cancer
Genentech, Inc. 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06600841
What this trial is testing

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer (PROC)Immunotherapy
Fujian Cancer Hospital 37
Testing effectiveness (Phase 2)Ended earlyNCT04019288
What this trial is testing

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05467670
What this trial is testing

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
Alexander B Olawaiye, MD 16
Large-scale testing (Phase 3)Looking for participantsNCT06994195
What this trial is testing

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 450
Testing effectiveness (Phase 2)Study completedNCT05130515
What this trial is testing

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

Who this might be right for
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 6
Large-scale testing (Phase 3)Ended earlyNCT04729608
What this trial is testing

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Aravive, Inc. 366
Next Page